Abstract:IMPORTANCE: Whole-genome sequencing (WGS) is increasingly applied in clinical medicine and is expected to uncover clinically significant findings regardless of sequencing indication.OBJECTIVES: To examine coverage and concordance of clinically relevant genetic variation provided by WGS technologies; to quantitate inherited disease risk and pharmacogenomic findings in WGS data and resources required for their discovery and interpretation; and to evaluate clinical action prompted by WGS findings.DESIGN, SETTING, AND PARTICIPANTS: An exploratory study of 12 adult participants recruited at Stanford University Medical Center who underwent WGS between November 2011 and March 2012. A multidisciplinary team reviewed all potentially reportable genetic findings. Five physicians proposed initial clinical follow-up based on the genetic findings.MAIN OUTCOMES AND MEASURES: Genome coverage and sequencing platform concordance in different categories of genetic disease risk, person-hours spent curating candidate disease-risk variants, interpretation agreement between trained curators and disease genetics databases, burden of inherited disease risk and pharmacogenomic findings, and burden and interrater agreement of proposed clinical follow-up.RESULTS: Depending on sequencing platform, 10% to 19% of inherited disease genes were not covered to accepted standards for single nucleotide variant discovery. Genotype concordance was high for previously described single nucleotide genetic variants (99%-100%) but low for small insertion/deletion variants (53%-59%). Curation of 90 to 127 genetic variants in each participant required a median of 54 minutes (range, 5-223 minutes) per genetic variant, resulted in moderate classification agreement between professionals (Gross κ, 0.52; 95% CI, 0.40-0.64), and reclassified 69% of genetic variants cataloged as disease causing in mutation databases to variants of uncertain or lesser significance. Two to 6 personal disease-risk findings were discovered in each participant, including 1 frameshift deletion in the BRCA1 gene implicated in hereditary breast and ovarian cancer. Physician review of sequencing findings prompted consideration of a median of 1 to 3 initial diagnostic tests and referrals per participant, with fair interrater agreement about the suitability of WGS findings for clinical follow-up (Fleiss κ, 0.24; P < 001).CONCLUSIONS AND RELEVANCE: In this exploratory study of 12 volunteer adults, the use of WGS was associated with incomplete coverage of inherited disease genes, low reproducibility of detection of genetic variation with the highest potential clinical effects, and uncertainty about clinically reportable findings. In certain cases, WGS will identify clinically actionable genetic variants warranting early medical intervention. These issues should be considered when determining the role of WGS in clinical medicine.

Scalable approaches for functional analyses of whole-genome sequencing non-coding variants

Exploring noncoding variants in genetic diseases: From detection to functional insights

Ultrafast and scalable variant annotation and prioritization with big functional genomics data

Decoding polygenic diseases: advances in noncoding variant prioritization and validation

From GWAS Variant to Function: A Study of ∼148,000 Variants for Blood Cell Traits

Non-coding genetic variants in human disease

Principles for the Post-Gwas Functional Characterisation of Risk Loci

Functional equivalence of genome sequencing analysis pipelines enables harmonized variant calling across human genetics projects

Bi-level Structured Functional Analysis for Genome-Wide Association Studies.

Technological advancements in functional interpretation of genome‐wide association studies (GWAS) findings: bridging the gap to clinical translation

Robust and Rapid Algorithms Facilitate Large-Scale Whole Genome Sequencing Downstream Analysis in an Integrative Framework

From GWAS to Gene: Transcriptome-Wide Association Studies and Other Methods to Functionally Understand GWAS Discoveries

Deep learning approaches for non-coding genetic variant effect prediction: current progress and future prospects

Prediction of disease-associated functional variants in noncoding regions through a comprehensive analysis by integrating datasets and features

Methods for the Analysis and Interpretation for Rare Variants Associated with Complex Traits.

Integrating Genetic Structural Variations and Whole-Genome Sequencing into Clinical Neurology

Whole genome sequencing in clinical practice

A Comparison on Predicting Functional Impact of Genomic Variants.

From GWAS to Function: Using Functional Genomics to Identify the Mechanisms Underlying Complex Diseases

Bioinformatics of germline variant discovery for rare disease diagnostics: current approaches and remaining challenges

Clinical Interpretation and Implications of Whole-Genome Sequencing